Close
  Indian J Med Microbiol
 

Figure 1: Percentage of patients achieving treatment targets with IDegLira compared with IGlar U100 at week 26 of DUAL VIII %, based on observed data. ORs (IDegLira/IGlar U100) are from a logistic regression model with treatment, baseline HbA1c group, pro-trial OAD, and region as factors and baseline HbA1c (and body weight for endpoints including “without weight gain”) as covariate. *Statistically significant difference (in favor of IDegLira). aSevere or blood glucose-confirmed (<3.1 mmol/L) symptomatic hypoglycemia was based on hypoglycemic episodes during a patient's last 12 weeks of treatment. IDetLira: Insulin degludec/liraglutide; IGlar U100: Insulin glargine 100 U/mL; OAD: Oral antidiabetic drug; OR: Odds ratio

Figure 1: Percentage of patients achieving treatment targets with IDegLira compared with IGlar U100 at week 26 of DUAL VIII %, based on observed data. ORs (IDegLira/IGlar U100) are from a logistic regression model with treatment, baseline HbA1c group, pro-trial OAD, and region as factors and baseline HbA1c (and body weight for endpoints including “without weight gain”) as covariate. *Statistically significant difference (in favor of IDegLira). aSevere or blood glucose-confirmed (<3.1 mmol/L) symptomatic hypoglycemia was based on hypoglycemic episodes during a patient's last 12 weeks of treatment. IDetLira: Insulin degludec/liraglutide; IGlar U100: Insulin glargine 100 U/mL; OAD: Oral antidiabetic drug; OR: Odds ratio